News

This study, part of the company’s broad oncology development program, will evaluate the safety, tolerability and initial response rates of MLN518 in combination with cytarabine and daunorubicin, the

Under the FDA modernization act of 1997, fast track designation allows the FDA to accept, on a rolling basis, portions of a marketing application prior to the completion

Antiplatelet agents prevent platelets from clumping or sticking together, which can cause formation of blood clots and lead to heart attack or stroke. Recent studies suggest that a

The first grant is a one-year “small business innovation research – advanced technology” (SBIR-AT) grant of $734,965, which will be used in the development of the company’s lead

The transaction provides MedImmune with three preclinical-stage programs developing monoclonal antibodies targeting the B-cell antigens CD19, CD20 and CD22. These antigens are believed to play important roles in

On February 28, 2005, Biogen Idec and Elan announced that they voluntarily suspended Tysabri from the US market and all ongoing clinical trials based on reports of progressive

The collaboration will focus on the optimization of lead compounds identified by Memory Pharmaceuticals and that have demonstrated effectiveness in the selective inhibition of PDE10 activity in several

Fodosine, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently in a phase IIa trial for patients with T-cell leukemia

This is the first preclinical study in which the injected cells were autologous, meaning they came from the animals’ own tissue, were not cultured, so that they did